Table 2.

Burden of non-SLN disease in studies with patients who underwent SLNB followed by completion ALND.

Study	Year	Largest tumor deposit on SLNB	Number of patients	Percent of patients with additional positive non-SLNs
Upfront Surgery
Giuliano et al.	2010	Any positive SLNa	365	27%
		Micrometastasis	137	10%
Galimberti et al.	2013	Micrometastasis	447	13%
Cserni et al. [44]	2008	Micrometastasis	435	18.2%
		Isolated tumor cells	82	8.5%
Donker et al.	2014	Any positive SLNa	744	33%
Savolt et al.	2017	Any positive SLNa	244	38.5%
NAC
Classe et al.	2019	Any positive SLNa	141	41.8%
Moo et al.	2018	Macrometastasis	121	62%
		Micrometastasis	44	64%
		Isolated tumor cells	6	17%
Sanders et al.	2022	Macrometastasis	201	58.6%
		Micrometastasis	26	38.5%
Boileau et al.	2015	Macrometastasis	61	56%
		Micrometastasis	8	38%
		Isolated tumor cells	7	57%

Abbreviations: ALND, axillary lymph node dissection; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; NAC, neoadjuvant chemotherapy.

^aAny positive SLN defined as any SLN with macrometastases, micrometastases, or isolated tumor cells.